MEF2C exon α: Role in gene activation and differentiation

Gene

Volumn 531, Issue 2, 2013, Pages 355-362

  Infantino, Vittoria ^a   Convertini, Paolo ^b   Menga, Alessio ^b   Iacobazzi, Vito ^b,c  

^a UNIVERSITY OF BASILICATA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c CNR   (Italy)

Author keywords

Differentiation; Gene expression; MEF2C; Splice variant; Transcription

Indexed keywords

MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2C; OLIGONUCLEOTIDE; PROTEIN VP; PROTEIN VP2; UBIQUITIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL STRAIN HEK293; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA BINDING; EMBRYO; EXON; EXON ALPHA; EXON SKIPPING; FEMALE; FLUORESCENCE IMAGING; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; WESTERN BLOTTING;

3-ISOBUTYL-1-METHYLXANTHINE; DB-CAMP; DIBUTYRYL-CAMP; DIFFERENTIATION; FOX1; GENE EXPRESSION; GFP; GREEN FLUORESCENT PROTEIN; IBMX; LUC; LUCIFERASE; MEF2C; MYOCYTE ENHANCER FACTOR 2C; RA; RETINOIC ACID; RNA BINDING PROTEIN FOX-1 HOMOLOG 1; SPLICE VARIANT; TRANSCRIPTION;

CELL DIFFERENTIATION; EXONS; GENETIC VARIATION; HEK293 CELLS; HELA CELLS; HUMANS; MEF2 TRANSCRIPTION FACTORS; NEUROGENESIS; NEURONS; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; TISSUE DISTRIBUTION; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

VERTEBRATA;

EID: 84885428188     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.08.044     Document Type: Article

References (35)

1. Abate C., et al. 2-Aminopyridine derivatives as potential sigma(2) receptor antagonists. ChemMedChem 2012, 7:1847-1857.
2. Bi W., Drake C.J., Schwarz J.J. The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF. Dev. Biol. 1999, 211:255-267.
3. Black B.L., Olson E.N. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu. Rev. Cell Dev. Biol. 1998, 14:167-196.
4. Cortes R., et al. Differences in MEF2 and NFAT transcriptional pathways according to human heart failure aetiology. PLoS One 2012, 7:e30915.
5. Depre C., et al. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat. Med. 1998, 4:1269-1275.
6. Edmondson D.G., Lyons G.E., Martin J.F., Olson E.N. Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development 1994, 120:1251-1263.
7. Fukumura K., et al. Tissue-specific splicing regulator Fox-1 induces exon skipping by interfering E complex formation on the downstream intron of human F1gamma gene. Nucleic Acids Res. 2007, 35:5303-5311.
8. Hakim N.H., Kounishi T., Alam A.H., Tsukahara T., Suzuki H. Alternative splicing of MEF2C promoted by Fox-1 during neural differentiation in P19 cells. Genes Cells 2010, 15:255-267.
9. Iacobazzi V., Infantino V., Costanzo P., Izzo P., Palmieri F. Functional analysis of the promoter of the mitochondrial phosphate carrier human gene: identification of activator and repressor elements and their transcription factors. Biochem. J. 2005, 391:613-621.
10. Iacobazzi V., Infantino V., Palmieri F. Epigenetic mechanisms and Sp1 regulate mitochondrial citrate carrier gene expression. Biochem. Biophys. Res. Commun. 2008, 376:15-20.
11. Iacobazzi V., Infantino V., Convertini P., Vozza A., Agrimi G., Palmieri F. Transcription of the mitochondrial citrate carrier gene: identification of a silencer and its binding protein ZNF224. Biochem. Biophys. Res. Commun. 2009, 386:186-191.
12. Infantino V., Iacobazzi V., De Santis F., Mastrapasqua M., Palmieri F. Transcription of the mitochondrial citrate carrier gene: role of SREBP-1, upregulation by insulin and downregulation by PUFA. Biochem. Biophys. Res. Commun. 2007, 356:249-254.
13. Infantino V., et al. Impairment of methyl cycle affects mitochondrial methyl availability and glutathione level in Down's syndrome. Mol. Genet. Metab. 2011, 102:378-382.
14. Infantino V., et al. The mitochondrial citrate carrier: a new player in inflammation. Biochem. J. 2011, 438:433-436.
15. Infantino V., Convertini P., Iacobazzi F., Pisano I., Scarcia P., Iacobazzi V. Identification of a novel Sp1 splice variant as a strong transcriptional activator. Biochem. Biophys. Res. Commun. 2011, 412:86-91.
16. Kalsotra A., et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20333-20338.
17. Kelemen O., et al. Function of alternative splicing. Gene 2013, 514:1-30.
18. Kuroyanagi H. Fox-1 family of RNA-binding proteins. Cell. Mol. Life Sci. 2009, 66:3895-3907.
19. Laghezza A., et al. New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor alpha/gamma dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression. J. Med. Chem. 2013, 56:60-72.
20. Leifer D., Golden J., Kowall N.W. Myocyte-specific enhancer binding factor 2C expression in human brain development. Neuroscience 1994, 63:1067-1079.
21. Lin Q., Schwarz J., Bucana C., Olson E.N. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 1997, 276:1404-1407.
22. Lin Q., et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 1998, 125:4565-4574.
23. Lyons G.E., Micales B.K., Schwarz J., Martin J.F., Olson E.N. Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. J. Neurosci. 1995, 15:5727-5738.
24. Magli A., et al. Proline isomerase Pin1 represses terminal differentiation and myocyte enhancer factor 2C function in skeletal muscle cells. J. Biol. Chem. 2010, 285:34518-34527.
25. Martin J.F., Miano J.M., Hustad C.M., Copeland N.G., Jenkins N.A., Olson E.N. A Mef2 gene that generates a muscle-specific isoform via alternative mRNA splicing. Mol. Cell. Biol. 1994, 14:1647-1656.
26. Park J.Y., et al. Comparative analysis of mRNA isoform expression in cardiac hypertrophy and development reveals multiple post-transcriptional regulatory modules. PLoS One 2011, 6:e22391.
27. Potthoff M.J., Olson E.N. MEF2: a central regulator of diverse developmental programs. Development 2007, 134:4131-4140.
28. Razeghi P., Young M.E., Alcorn J.L., Moravec C.S., Frazier O.H., Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 2001, 104:2923-2931.
29. Shore P., Sharrocks A.D. The MADS-box family of transcription factors. Eur. J. Biochem. 1995, 229:1-13.
30. Stamm S. Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum. Mol. Genet. 2002, 11:2409-2416.
31. Tio M., Tan K.H., Lee W., Wang T.T., Udolph G. Roles of db-cAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells. PLoS One 2010, 5:e9398.
32. Wu W., de Folter S., Shen X., Zhang W., Tao S. Vertebrate paralogous MEF2 genes: origin, conservation, and evolution. PLoS One 2011, 6:e17334.
33. Xu J., Gong N.L., Bodi I., Aronow B.J., Backx P.H., Molkentin J.D. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. J. Biol. Chem. 2006, 281:9152-9162.
34. Zhu B., Gulick T. Phosphorylation and alternative pre-mRNA splicing converge to regulate myocyte enhancer factor 2C activity. Mol. Cell. Biol. 2004, 24:8264-8275.
35. Zhu B., Ramachandran B., Gulick T. Alternative pre-mRNA splicing governs expression of a conserved acidic transactivation domain in myocyte enhancer factor 2 factors of striated muscle and brain. J. Biol. Chem. 2005, 280:28749-28760.